Integrating precision medicine: are we ready for a paradigm shift in advanced urothelial carcinoma?

Learning objectives:

After attending this meeting, participants should be able to:

• Differentiate current metastatic urothelial carcinoma treatment options and describe their applicability in clinical practice
• Evaluate tumour biology, the role of biomarkers, and the challenges of advanced urothelial carcinoma from a multidisciplinary perspective
• Describe how current research may drive therapeutic decisions for patients with advanced urothelial carcinoma in the future

Faculty:

• Maria De Santis (Germany)
• Joaquim Bellmunt (USA)
• Eva Comperat (France)
• Yohann Loriot (France)
• Shahrokh Shariat (Austria)
• Arlene Siefker-Radtke (USA)